Skip to main content
Retour
VTRS logo

Viatris Inc.

Qualité des données : 100%
VTRS
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
13,36 €
▲ 0,07 € (0,53%)
Cap. Boursière : 15,39B
Fourchette du Jour
13,11 € 13,49 €
Fourchette 52 Semaines
6,85 € 16,47 €
Volume
7 650 568
Moyenne 50J / 200J
14,22 € / 11,17 €
Clôture Précédente
13,29 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -4,4 0,4
P/B 1,1 2,9
ROE % -21,1 3,7
Net Margin % -24,6 3,9
Rev Growth 5Y % -5,4 10,0
D/E 1,0 0,2

Objectif de Cours des Analystes

Hold
15,25 € +14.1%
Low: 12,00 € High: 18,00 €
P/E Prévisionnel
5,4
BPA Prévisionnel
2,45 €
Croissance BPA (est.)
+0,0%
CA Est.
15 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2029 0,00 €
0,00 € – 0,00 €
15 B 0
FY2028 3,25 €
1,49 € – 5,02 €
15 B 2
FY2027 2,67 €
2,36 € – 2,77 €
15 B 5

Points Clés

Revenue declined -5,44% annually over 5 years
Generating 1,94B in free cash flow
Capital efficient — spends only 2,65% of revenue on capex

Croissance

Revenue Growth (5Y)
-5,44%
Revenue (1Y)-2,98%
Earnings (1Y)N/A
FCF Growth (3Y)-8,72%

Qualité

Return on Equity
-21,08%
ROIC-6,79%
Net Margin-24,58%
Op. Margin-18,62%

Sécurité

Debt / Equity
1,00
Current Ratio1,30
Interest Coverage-5,65

Valorisation

P/E Ratio
-4,38
P/B Ratio1,05
EV/EBITDAN/A
Dividend Yield0,04%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -2,98% Revenue Growth (3Y) -3,72%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -5,44% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 14,30B Net Income (TTM) -3,51B
ROE -21,08% ROA -9,45%
Gross Margin 35,06% Operating Margin -18,62%
Net Margin -24,58% Free Cash Flow (TTM) 1,94B
ROIC -6,79% FCF Growth (3Y) -8,72%
Safety
Debt / Equity 1,00 Current Ratio 1,30
Interest Coverage -5,65 Dividend Yield 0,04%
Valuation
P/E Ratio -4,38 P/B Ratio 1,05
P/S Ratio 1,08 PEG Ratio -0,01
EV/EBITDA N/A Dividend Yield 0,04%
Market Cap 15,39B Enterprise Value 28,74B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 14,30B 14,74B 15,43B 16,26B 17,89B
Net Income -3,51B -634,20M 54,70M 2,08B -1,27B
EPS (Diluted) -3,00 -0,53 0,05 1,71 -1,05
Gross Profit 5,01B 5,62B 6,44B 6,50B 5,58B
Operating Income -2,66B 10,10M 766,20M 1,61B -34,00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 37,19B 41,50B 47,69B 50,02B 54,84B
Total Liabilities 22,48B 22,87B 27,22B 28,95B 34,35B
Shareholders' Equity 14,71B 18,64B 20,47B 21,07B 20,49B
Total Debt 14,70B 14,31B 18,37B 19,53B 23,36B
Cash & Equivalents 1,35B 734,80M 991,90M 1,26B 701,20M
Current Assets 9,22B 9,52B 12,98B 10,64B 10,90B
Current Liabilities 7,09B 5,78B 7,78B 6,75B 9,88B